Objective To explore the clinical mechanism of Qili Qiangxin Capsule on blood lipid metabolism and hemorheology in patients with angina pectoris of coronary heart disease.
Methods A total of 100 coronary heart disease patients with angina pectoris admitted to our hospital from April 2020 to August 2021 were recruited as the research objects. According to the principle of random grouping, they were divided into observation group and control group with 50 cases each group. The control group was treated with conventional treatment measures, and the observation group was treated with Qiliqiangxin capsule on the basis of conventional treatment. All patients had informed consent and signed an informed consent form before participating in the study. The general data of patients are counted according to the file information. The hemorheology indexes of patients before and after treatment were analyzed with automatic hemorheometer. Automatic biochemical analyzer was used to detect blood lipid of patients. The TCM syndrome score was conducted according to the Guiding Principles for Clinical Research of New Chinese Medicine, and the degree of coronary artery stenosis was analyzed through coronary artery CT and OCT examinations and images. Enzyme linked immunosorbent assay was used to detect the level of inflammation before and after treatment. The therapeutic effects of the two groups were analyzed.
Results After treatment, hemorheological related indexes in the two groups were lower than before treatment, and the hemorheological related indexes in the observation group were lower than those in the control group (P < 0.05). Total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) were decreased after treatment, while high density lipoprotein cholesterol (HDL-C) was increased after treatment, and the above indexes in the observation group showed statistically significant differences compared with the control group (P < 0.05). After treatment, TCM syndrome score and coronary artery stenosis degree of the two groups were lower than before treatment, and were lower in the observation group than those in the control group (P < 0.05). After treatment, the levels of tumor necrosis factor-α (TNF-α), soluble urokinase plasminogen activator receptor (suPAR) and C-reactive protein (CRP) in the two groups were lower than before treatment, and their levels in the observation group were lower than those in the control group (P < 0.05). The total effective rate was 84.00%, which was higher than 66.00% in the control group, and the difference was statistically significant (P < 0.05).
Conclusion Qili Qiangxin Capsules can significantly improve the clinical symptoms of patients with coronary heart disease and angina pectoris, reduce blood lipid levels, regulate lipoprotein metabolism disorders, improve blood rheology indicators, and reduce blood viscosity.
DownLoad: